Stephens Investment Management Group LLC Has $77.83 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Stephens Investment Management Group LLC decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.4% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,359,730 shares of the biopharmaceutical company’s stock after selling 62,174 shares during the period. Stephens Investment Management Group LLC owned about 1.07% of Halozyme Therapeutics worth $77,831,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Whittier Trust Co. purchased a new stake in shares of Halozyme Therapeutics in the first quarter worth approximately $27,000. GAMMA Investing LLC grew its holdings in shares of Halozyme Therapeutics by 96.6% during the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 254 shares in the last quarter. International Assets Investment Management LLC purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at $33,000. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Halozyme Therapeutics in the second quarter worth $49,000. Finally, Fidelis Capital Partners LLC purchased a new stake in shares of Halozyme Therapeutics during the first quarter worth $52,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HALO has been the topic of a number of recent research reports. The Goldman Sachs Group boosted their target price on Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research note on Monday, July 22nd. Benchmark restated a “buy” rating and issued a $60.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Morgan Stanley lifted their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price target for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Finally, Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $60.44.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $52.58, for a total value of $525,800.00. Following the sale, the chief executive officer now directly owns 676,744 shares in the company, valued at $35,583,199.52. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $52.58, for a total transaction of $525,800.00. Following the sale, the chief executive officer now owns 676,744 shares in the company, valued at $35,583,199.52. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Matthew L. Posard sold 9,881 shares of the stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total transaction of $570,133.70. Following the completion of the transaction, the director now owns 69,874 shares of the company’s stock, valued at approximately $4,031,729.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 89,881 shares of company stock valued at $5,169,834. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Trading Down 0.0 %

Shares of NASDAQ:HALO opened at $50.57 on Friday. The company has a debt-to-equity ratio of 5.19, a quick ratio of 6.21 and a current ratio of 7.41. The stock’s 50-day moving average is $57.32 and its 200-day moving average is $51.82. The company has a market cap of $6.41 billion, a P/E ratio of 19.60, a P/E/G ratio of 0.49 and a beta of 1.27. Halozyme Therapeutics, Inc. has a 52-week low of $33.07 and a 52-week high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The firm had revenue of $231.40 million for the quarter, compared to analyst estimates of $204.94 million. During the same quarter last year, the firm posted $0.68 EPS. The company’s revenue was up 4.7% on a year-over-year basis. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.